BMS' Biologic Emplicti (Elotuzumab) Receives Approval in the U.S.
SAN FRANCISCO--(BUSINESS WIRE)--Indapta Therapeutics, Inc., a biotechnology company developing and commercializing an NK (natural killer) cell therapy platform for the treatment of blood cancers and solid tumors, today announced the publication of new preclinical data in Blood Advances demonstrating Indapta’s proprietary allogeneic FcεRIγ-deficient G-NK cells in combination with an FDA-approved monoclonal antibody (mAb) resulted in greater than 99.9% tumor reduction in a preclinical cancer regression model of multiple myeloma compared to conventional NK cells. G-NK cells are a naturally occurring subset of NK cells that when expanded and “turbocharged” using Indapta’s proprietary manufacturing process, boost the efficacy of mAbs and can overcome the cost, inconsistency, and possible toxicities associated with autologous T-cell therapies commonly used in the treatment of multiple myeloma.
Bristol Myers Empliciti (Elotuzumab) Receives Supplemental Approval in US
Less than a year after the FDA cleared Bristol-Myers Squibb $BMY and AbbVie’s $ABBV approved Empliciti injection for intravenous use in combination with Celgene’s $CELG pomalidomide (Pomalyst, or Imnovid, depending on which side of the Atlantic you are) and the steroid dexamethasone for relapsed, refractory multiple myeloma, the European Commission has followed suit.
The European Commission (EC) has approved Bristol-Myers Squibb’s
As expected, the European Commission approves Bristol-Myers Squibb's (NYSE:BMY) Empliciti (elotuzumab), combined with Celgene's Pomalyst (pomalidomide) and low-dose dexamethasone, for the treatment of adult patients with multiple myeloma (MM) who have received at least two prior lines of therapy, including Celgene's REVLIMID (lenalidomide) and a proteosome inhibitor and have progressed on the last therapy.
Right now, the first infusion of Johnson & Johnson multiple myeloma fighter Darzalex can take between seven and eight hours. But data on a new formulation could be a game changer. At the American Society of Clinical Oncology annual meeting, the New Jersey drugmaker trumpeted results from a phase 3 study showing that a subcutaneous form of Darzalex could measure up to the original—and with an average injection time of just five minutes.
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced the presentation of data from across the company’s oncology portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting 2019 in Chicago, May 31-June 4, and the 24th Annual Congress of the European Hematology Association (EHA) in Amsterdam, June 13-16. Data from over 90 Company-sponsored studies, investigator-sponsored studies and collaborations evaluating oncology compounds and early translational medicine across 20 types of cancer will be featured at the two meetings. Presentations will highlight the role of Immuno-Oncology (I-O) monotherapy and combination approaches in improving survival and quality of life outcomes, as well as translational research investigating novel biomarkers and diagnostics to aid in the selection of tailored treatments for each patient based on their unique disease biology.
Bristol Myers Squibb` Biological Empliciti(Elotuzumab) Receives Supplemental Approval in US
US regulators have expanded the treatment scope of Bristol-Myers Squibb’s Empliciti allowing its use plus pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.